Merck (MRK) Tops Q2 EPS by 12c; Raises Guidance

Merck (NYSE: MRK) reported Q2 EPS of ($2.06), $0.12 better than the analyst estimate of ($2.18). Revenue for the quarter came in at $15 billion versus the consensus estimate of $14.43 billion.

GUIDANCE:

Merck sees FY2023 EPS of $2.95-$3.05, versus the consensus of $2.60. Merck sees FY2023 revenue of $58.6-59.6 billion, versus the consensus of $53.2 billion.

For earnings history and earnings-related data on Merck (MRK) click here.

You May Also Be Interested In

• Micron Technology (MU) Tops Q3 EPS by $4.62, Guidance Beats
• H.B. Fuller makes £715M cash offer to acquire Advanced Medical Solutions
• MillerKnoll, Inc. (MLKN) Tops Q4 EPS by 4c